- Miracle chemical ‘cocktail’ could cure spinal cord damage
- Combined expression of pro-regenerative transcription factors and transplanted stem cells to promote corticospinal tract regeneration.
- Structural and Functional Substitution of Deleted Primary Sensory Neurons by New Growth from Intrinsic Spinal Cord Nerve Cells: An Alternative Concept in Reconstruction of Spinal Cord Circuits
- U2FP SCI CureCast now includes the 8th episode!
- Chronic SCI: ReNetX Bio Launched to Advance Innovative Neuro-Regenerative Technology Developed at Yale University
- Overexpression of KLF6 in corticospinal tract neurons promotes axon growth after spinal injury
- A potent anti-spastic effect after intrathecal NK1 antisense oligonucleotide or subpial AAV9-NK1-ShRNA delivery in rats with chronic spinal transection-induced muscle spasticity
- Non-Invasive Paired Stimulation and Anklebot Robot to Improve Lower Extremity Motor Recovery in Chronic Spinal Cord Injury
- Spinal cord injury: Using cortical targets to improve motor function
- 43 Disability Protesters outside of Senate Mitch McConnell’s office arrested over proposed severe Medicaid cuts.
- Interaction of reactive astrocytes with type I collagen induces astrocytic scar formation through the integrin–N-cadherin pathway after SCI
- SCI Stem-cell pioneer enters the political field in California
- Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias’ AST-OPC1
- Induction of immune tolerance by short-course immunosuppresion after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury.
- Growth Hormone Improves Sensory Function in Complete Spinal Injury
Follow on TwitterMy Tweets
Tag Archives: Neuralstem
Induction of immune tolerance by short-course immunosuppresion after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury.
Current clinical protocols use transient or continuous immunosuppression in patients receiving allogeneic neural precursor grafts for treatment of a variety of neurological diseases, including spinal trauma, stroke or ALS. At present there is no solid evidence, however, that would confirm … Continue reading
I frequently check in to see what’s happening at the Paul Knoepfler Stem Cell blog. His post yesterday took me by complete surprise. Even though SCI isn’t part of the PTT Law, this will be an interesting situation to follow. … Continue reading
Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego (NSI-566 to be Tested in Patients with Chronic Spinal Cord Injury)
Neuralstem, Inc. announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the Phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI Phase … Continue reading
Richard Garr, President & CEO of Neuralstem gives his presentation on ‘Understanding the Practicalities of Using Innovative Therapies on Patients’ at the World Stem Cells & Regenerative Medicine Congress 2013.
ROCKVILLE, Md., Jan. 14, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, … Continue reading